All-cause and cardiovascular mortality risk estimation using different definitions of metabolic syndrome in Lithuanian urban population

Lukšienė, Dalia; Bacevičienė, Miglė; Jurėnienė, Kristina; Bernotienė, Gailutė; Rėklaitienė, Regina; Radišauskas, Ričardas; Tamošiūnas, Abdonas

doi:10.1016/j.ypmed.2012.08.002

Cited by 7 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, WHO-MetS which has higher threshold for high blood pressure, central obesity and fasting plasma glucose gives less weight to these components and on average identifies only individuals with more severe conditions and higher risk for CVD or total mortality. In line with our finding, previous reports showed that lower cut-offs for these components in more recent definitions such as IDF and JIS lead to a higher prevalence and lower predictive risk [22,23]. Therefore it seems that the increased risk of CVD and all-cause mortality in patients with WHO-MetS can be attributed to the presence of dysglycemia per se rather than to MetS itself as an entity, demonstrating a high overlap between MetS and dysglycemia, but indicates no added predictive value of MetS for CVD risk [24].…”

Section: Discussionsupporting

confidence: 93%

“…In a Chinese cohort of 1535 subjects, aged 50 years or older, MetS was associated with excess risk of all-cause mortality only in men [34]. A Lithuanian cohort of 2455 subjects, aged 35-64 years, showed an association between MetS (defined by JIS and IDF) and all-cause and CVD mortality in men [23]. In contrast to these studies, an Italian cohort of 1960, subjects aged 65 years showed that women diagnosed with MetS based on the NCEP, NCEP-R, JIS and IDF definitions had higher risk of all-cause mortality, whereas in men, mortality risk was not associated to MetS [35].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The predictive value of metabolic syndrome for cardiovascular and all‐cause mortality: Tehran Lipid and Glucose Study

Amouzegar

Mehran

Hasheminia

et al. 2016

Diabetes Metabolism Res

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

The predictive value of metabolic syndrome for cardiovascular and all‐cause mortality: Tehran Lipid and Glucose Study

Amouzegar

Mehran

Hasheminia

et al. 2016

Diabetes Metabolism Res

View full text Add to dashboard Cite

show abstract

“…Also in line with our findings, previous literature has shown positive associations between MetS and CVD mortality in retrospective and prospective cohort designs or studies using health care data and focusing on specific populations (i.e. American and Iranian) [23,[41][42][43].…”

Section: Discussionsupporting

confidence: 92%

Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study

Mayén,

Sabra,

Aglago

et al. 2024

BMC Med

View full text Add to dashboard Cite

Background Non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MetS) are implicated in the aetiology of non-communicable diseases. Our study aimed to evaluate associations between NAFLD and MetS with overall and cause-specific mortality. Methods We used dietary, lifestyle, anthropometric and metabolic biomarker data from a random subsample of 15,784 EPIC cohort participants. NAFLD was assessed using the fatty liver index (FLI) and MetS using the revised definition. Indices for metabolic dysfunction–associated fatty liver disease (MAFLD) were calculated. The individual associations of these indices with overall and cause-specific mortality were assessed using multivariable Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (95%CIs). As a subobjective, risk associations with adaptations of new classifications of metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic and alcohol-related liver disease (MetALD) were also assessed. Results Among the 15,784 sub-cohort participants, a total of 1997 deaths occurred (835 due to cancer, 520 to CVD, 642 to other causes) over a median 15.6 (IQR, 12.3–17.1) years of follow-up. Compared to an FLI < 30, FLI ≥ 60 was associated with increased risks of overall mortality (HR = 1.44, 95%CI = 1.27–1.63), and deaths from cancer (HR = 1.32, 95%CI = 1.09–1.60), CVD (HR = 2.06, 95% CI = 1.61–2.63) or other causes (HR = 1.21, 95%CI = 0.97–1.51). Mortality risk associations were also elevated for individuals with MAFLD compared to those without. Individuals with MetS were at increased risk of all mortality endpoints, except cancer-specific mortality. MASLD and MetALD were associated with higher risk of overall mortality. Conclusions Our findings based on a prospective cohort suggest that individuals with hepatic steatosis or metabolic dysfunction have a higher overall and cause-specific mortality risk.

show abstract

“…In previous analysis of Kaunas data it was shown that metabolic syndrome defined by International Diabetes Federation (IDF) and new Joint Interim Societies (JIS) definitions remained the only significant determinants for all-cause mortality and CVD mortality in men (without previous CVD); however, in women the metabolic syndrome was not associated with CVD mortality risk [34].…”

Section: Discussionmentioning

confidence: 99%

Trends in Prevalence of Dyslipidaemias and the Risk of Mortality in Lithuanian Urban Population Aged 45–64 in Relation to the Presence of the Dyslipidaemias and the Other Cardiovascular Risk Factors

et al. 2014

Self Cite

View full text Add to dashboard Cite

The aim of this study was to provide reliable information on dyslipidaemias, to estimate the trend of the prevalence of dyslipidaemias and other selected cardiovascular disease (CVD) risk factors at population level, and to evaluate the risk of all-cause and CVD mortality in relation to presence of mixed dyslipidaemias and other CVD risk factors.MethodsData from the five surveys (1983–2008) are presented. A random sample of 9,209 subjects aged 45–64 was selected for statistical analysis. During follow-up there were 1653 death cases from any cause, 864 deaths from CVD. Estimates of hazard ratios (HR) and 95% confidence intervals (CI) were based on the multivariate Cox proportional hazards regression for all-cause mortality and CVD mortality.ResultsDuring 25 year period the prevalence of normal total cholesterol level (<5.2 mmol/L) significantly increased only in women; triglycerides and high density lipoprotein (HDL) cholesterol did not change in men and women. Findings in our longitudinal study showed that in men and women mixed dyslipidaemias (HDL cholesterol <1.03 mmol/L plus triglycerides ≥1.70 mmol/L) significantly increased the risk for all-cause and CVD mortality (respectively in men HR = 1.30; HR = 1.15, in women HR = 1.83; HR = 2.13). These mixed dyslipidaemia combinations combination with the other risk factors such as arterial hypertension, high fasting glucose level increased all-cause and CVD mortality risk in men and women; while, these mixed dyslipidaemias plus smoking increased all-cause and CVD mortality risk only in men compared to never smokers without these dyslipidaemias (respectively HR = 1.89; HR = 1.92); and these dyslipidaemias plus obesity increased all-cause and CVD mortality risk in women (respectively HR = 2.25; HR = 2.39) and CVD mortality risk in men (HR = 1.72), as compared to responders without obesity and these dyslipidaemias.ConclusionMixed dyslipidaemias (reduced HDL cholesterol plus elevated triglycerides) significantly increased the risk for all-cause and CVD mortality in this Lithuanian population aged 45–64 years.

show abstract

All-cause and cardiovascular mortality risk estimation using different definitions of metabolic syndrome in Lithuanian urban population

Cited by 7 publications

References 24 publications

The predictive value of metabolic syndrome for cardiovascular and all‐cause mortality: Tehran Lipid and Glucose Study

The predictive value of metabolic syndrome for cardiovascular and all‐cause mortality: Tehran Lipid and Glucose Study

Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study

Trends in Prevalence of Dyslipidaemias and the Risk of Mortality in Lithuanian Urban Population Aged 45–64 in Relation to the Presence of the Dyslipidaemias and the Other Cardiovascular Risk Factors

Contact Info

Product

Resources

About